COCP Cocrystal Pharma Inc

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Thursday, October 9, 2025 at 12:00 pm Eastern time (9:00 a.m. Pacific time). The formal presentation will be followed by a hosted question-and-answer session with questions welcomed from the live virtual audience.

Those interested in viewing the live Cocrystal presentation can register for the event . A video webcast of the presentation will be available within 48 hours following the event on the Company's and archived for 90 days.

Mr. Martin will be available throughout the conference for virtual one-on-one meetings with registered, qualified investors. Meetings can be scheduled by contacting Giorgia Pigato at Noble Capital Markets.

About Noble Capital Markets, Inc. 

is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2018, Noble launched —an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer investors free institutional-quality research without a subscription.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Contact:

Alliance Advisors IR

Jody Cain

310-691-7100

# # #



EN
02/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates o...

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial result...

 PRESS RELEASE

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating C...

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 09, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company...

 PRESS RELEASE

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to ...

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Comp...

 PRESS RELEASE

Cocrystal Pharma Receives IRB Approval from Emory University School of...

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infectionThere are no approved treatments or vaccines currently available for norovirus infection BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) an...

 PRESS RELEASE

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emergin...

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida. Interested investors and guests of Cocr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch